Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of Fructosamine Levels With Glycemic Control in Children With Type 1 Diabetes as Determined by Continuous Glucose Monitoring: Results From the CGM TIME Trial.
Verbeeten KC, Tang K, Courtney JM, Bradley BJ, McAssey K, Clarson C, Kirsch S, Curtis JR, Mahmud FH, Richardson C, Cooper T, Lawson ML; CGM TIME Trial Study Group; JDRF Canadian Clinical Trials Group. Verbeeten KC, et al. Among authors: mahmud fh. Can J Diabetes. 2024 Apr 16:S1499-2671(24)00073-X. doi: 10.1016/j.jcjd.2024.04.007. Online ahead of print. Can J Diabetes. 2024. PMID: 38614216
Renal and Cardiovascular Risk According to Tertiles of Urinary Albumin-to-Creatinine Ratio: The Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT).
Marcovecchio ML, Chiesa ST, Armitage J, Daneman D, Donaghue KC, Jones TW, Mahmud FH, Marshall SM, Neil HAW, Dalton RN, Deanfield J, Dunger DB; Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT) Study Group. Marcovecchio ML, et al. Among authors: mahmud fh. Diabetes Care. 2018 Sep;41(9):1963-1969. doi: 10.2337/dc18-1125. Epub 2018 Jul 19. Diabetes Care. 2018. PMID: 30026334 Free article.
Socioeconomic representativeness of Australian, Canadian and British cohorts from the paediatric diabetes AdDIT study: comparisons to regional and national data.
Mahmud FH, Clarke ABM, Elia Y, Curtis J, Benitez-Aguirre P, Cameron FJ, Chiesa ST, Clarson C, Couper JJ, Craig ME, Dalton RN, Daneman D, Davis EA, Deanfield JE, Donaghue KC, Jones TW, Marshall SM, Neil A, Marcovecchio ML. Mahmud FH, et al. BMC Med. 2023 Dec 20;21(1):506. doi: 10.1186/s12916-023-03222-w. BMC Med. 2023. PMID: 38124088 Free PMC article.
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Laffel LM, et al. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
ISPAD Clinical Practice Consensus Guidelines 2022: Editorial.
Craig ME, Codner E, Mahmud FH, Marcovecchio ML, DiMeglio LA, Priyambada L, Wolfsdorf JI. Craig ME, et al. Among authors: mahmud fh. Pediatr Diabetes. 2022 Dec;23(8):1157-1159. doi: 10.1111/pedi.13441. Pediatr Diabetes. 2022. PMID: 36537535 Free PMC article. No abstract available.
96 results